Preston Klassen
CIK 1493056 · President & Head of R & D · last filed 2025-06-27
Preston Klassen is a President & Head of R & D who has filed 39 SEC Form 4 insider transactions across 5 companies since 2010. The most recent filing, for RGLS, was dated Jun 27, 2025. Across all open-market trades the lifetime net is −$1.6M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
5
39
-$1.57M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Regulus Therapeutics Inc. (RGLS) Delisted | President & Head of R & D | 0 | $8.16 | $0 | $56.1K | 9 | 2025-06-27 |
| Metacrine, Inc. (MTCR) Delisted | President & CEO | 541,905 | $0.49 | $268.2K | -$105.0K | 6 | 2023-01-27 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | EVP and CMO | 3,991 | $99.99 | $399.1K | -$799.1K | 5 | 2020-03-03 |
| Histogen Inc. (CNAT) Delisted | Director | — | — | — | $0 | 6 | 2019-07-01 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | EVP, Global Development | 10,160 | — | — | -$717.4K | 12 | 2016-02-04 |
Recent Filings
39 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-27 | Regulus Therapeutics Inc. (RGLS) Delisted | Disp (D) | −115,555 | $0 | EDGAR |
| 2025-06-04 | Regulus Therapeutics Inc. (RGLS) Delisted | Buy (P) | +12,000 | $95.9K | EDGAR |
| 2025-01-31 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-15 | Regulus Therapeutics Inc. (RGLS) Delisted | Sell (S) | −31,445 | -$39.7K | EDGAR |
| 2025-01-10 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | +67,500 | $90.0K | EDGAR |
| 2024-05-21 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-17 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-08-14 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-12 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-03-24 | — | Mixed | −842,211 | -$395.8K |